Filter
1671
Text search:
hepatitis
E
Featured
230
494
Language
Document type
884
351
192
95
59
28
28
16
6
3
3
2
1
Countries
100
52
46
45
37
35
32
31
29
28
26
26
25
24
24
23
23
21
20
19
19
19
18
17
16
13
12
12
10
10
10
8
7
7
7
6
6
6
6
6
6
6
6
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
670
199
106
92
73
32
25
1
Toolboxes
179
133
80
78
75
57
54
48
36
32
32
29
24
24
24
23
15
12
9
8
7
6
3
2
1
Los objetivos de las guías son brindar directrices para optimizar el cuidado de la mayoría de los pacientes afectados por los VHB y VHC. Sin embargo, no reemplazan el criterio médico en la valoración y abordaje del paciente individual. En situaciones especiales, el mejor enfoque en el diagnóst
...
The five hepatitis viruses have different epidemiological profiles, and their impact, duration, and transmission route also vary. The most common transmission routes contributing to the spread of hepatitis
...
En estas directrices se actualiza la sección de recomendaciones sobre la prevención de la transmisión maternoinfantil de las Directrices para la prevención, la atención y el tratamiento de la infección crónica por el virus de la hepatitis B,
...
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnosti
...
J Hepatol (2017), http://dx.doi.org/10.1016/j.jhep.2017.03.021
Guidelines on hepatitis B and C testing
recommended
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis
...
The document describes the use of strategic information at various stages of the response in the context of strengthening broader health information systems. Strategic information can be defined as data collected at all service delivery and administrative levels to inform policy and programme decisi
...
The Global hepatitis report 2026 provides the most comprehensive and up-to-date assessment of the global burden of hepatitis B (HBV) and hepatitis
...
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
shoul
...
WHO estimates that in 2015, 257 million people were living with chronic hepatitis B virus (HBV) infection worldwide, and that 900 000 died from HBV infection, mostly through the development of cirrhosis and hepatocellular carcinoma. Worldwide, the m
...
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis
...
Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease.
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment cri
...
Progress report and road map. Countries included in this report: Algeria, Afghanistan, Bahrain, Djibouti, Egypt, the Islamic Republic of Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Qatar, State of Palestine, Saudi Arabia, Somalia, Sudan, the Syrian Arab Republic, Tunisia, Un
...
This document consolidates, for the first time, WHO recommendations on the prevention, testing, treatment and monitoring of hepatitis B and C, and includes testing strategies for hepatitis D. Drawin
...
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has impr
...
The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera
...
